Mount Sinai's Icahn School of Medicine jumps into Dx, drug development

The Icahn School of Medicine at Mount Sinai in New York will team with a Massachusetts biopharmaceutical company to develop new diagnostics and drugs for cancer, plus central nervous system and endocrine disorders. Its 5-year partnership with Berg is expected to focus, in part, on developing diagnostic tools that can spot disease better and also mark how well a treatment is working. They'll pursue projects in areas including genomics, proteomics, lipidomics and metabolomics. Item

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.